Gufic BiosciencesGUFICBIO 
-1.77%24h
Gufic Biosciences (GUFICBIO) Stock Overview
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
GUFICBIO Stock Information
Gufic Biosciences (GUFICBIO) Price Chart
Gufic Biosciences Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $4.80 | N/A |
| Market Cap | $465.16M | N/A |
| Shares Outstanding | 96.96M | 0.06% |
| Employees | 1.63K | N/A |
| Shareholder Equity | 3.48B | 29.24% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | 0.58 | N/A |
| P/S Ratio | 5.65 | N/A |
| P/B Ratio | 0.13 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.0027 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $82.34M | N/A |
| Earnings | $9.50M | N/A |
| EPS | 8.22 | N/A |
| Earnings Yield | 1.71 | N/A |
| Gross Margin | 0.5195 | N/A |
| Operating Margin | 0.1627 | N/A |
| Net income margin | 0.1154 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $102.68M | N/A |
| Total Debt | $39.85M | N/A |
| Cash on Hand | $5.57M | N/A |
| Debt to Equity | 0.0176 | 57.44% |
| Cash to Debt | 0.1397 | -66.15% |
| Current Ratio | $1.61 | -6.13% |
